How Much Does Zepbound Cost in New Jersey in 2026?

Zepbound Retail Pricing in New Jersey

The manufacturer list price for Zepbound is $1,059 per month across all six dose strengths, and New Jersey retail pharmacies generally charge this same amount for cash-pay customers [1]. This price applies whether a patient fills at a chain pharmacy in Newark, a local independent in Princeton, or a mail-order pharmacy shipping to a New Jersey address.

Why the Price Is Uniform Across NJ

Eli Lilly sets a single wholesale acquisition cost (WAC) for Zepbound nationwide. Unlike some generics, branded tirzepatide has no competing manufacturers that could drive regional price variation [2]. Pharmacy markup on specialty injectables in New Jersey typically adds $0 to $15 above WAC for cash-pay transactions, keeping total cost near the $1,059 figure.

How Zepbound Compares to Mounjaro Pricing

Mounjaro (also tirzepatide) carries the same $1,059 monthly list price but is indicated for type 2 diabetes rather than weight management [1]. Insurance formulary placement differs between the two. A patient with diabetes may find Mounjaro on a preferred tier while Zepbound requires step therapy or prior authorization, even though the active molecule is identical [3].

Insurance Coverage for Zepbound in New Jersey

Commercial insurance plans in New Jersey vary widely in Zepbound coverage. Some major carriers place it on specialty tiers with prior authorization, while others exclude anti-obesity medications entirely from their formularies [3].

Plans That Commonly Cover Zepbound

Horizon Blue Cross Blue Shield of New Jersey, the state's largest insurer, has added GLP-1 receptor agonist coverage to select employer-sponsored plans. Aetna and UnitedHealthcare offer Zepbound on certain commercial plans but typically require documentation of BMI ≥30 (or ≥27 with at least one weight-related comorbidity such as hypertension or type 2 diabetes), consistent with the FDA-approved indication [1][4].

Prior Authorization Requirements

Most New Jersey insurers that cover Zepbound require prior authorization. Standard criteria include: a documented BMI meeting FDA thresholds, failure of lifestyle modification for at least 3 to 6 months, and sometimes trial of an older agent such as phentermine or orlistat [4]. Processing typically takes 5 to 14 business days.

Self-Funded Employer Plans

Large New Jersey employers with self-funded health plans make independent formulary decisions. Some have added Zepbound coverage after internal cost-benefit analyses showed reduced downstream spending on bariatric surgery, obstructive sleep apnea treatment, and cardiovascular events [5]. Employees should check their specific plan documents or call the number on their insurance card.

New Jersey Medicaid and Zepbound

New Jersey Medicaid covers Zepbound with prior authorization [4]. This makes New Jersey one of the states where Medicaid beneficiaries can access tirzepatide for chronic weight management, though the approval process requires clinical documentation.

What Medicaid Prior Auth Requires

NJ FamilyCare (the state's Medicaid program) requires prescribers to submit documentation of the patient's BMI, weight-related comorbidities, and a record of attempted behavioral interventions [4]. The Medicaid Drug Utilization Review Board reviews anti-obesity medication requests against the FDA label criteria [1]. Approval typically covers an initial 6-month period with renewal contingent on demonstrated weight loss of at least 5% from baseline.

Medicare Part D Limitations

Medicare Part D does not cover anti-obesity medications, including Zepbound [6]. Medicare beneficiaries in New Jersey must pay cash, use compounded alternatives, or explore Eli Lilly's direct savings programs. Proposed federal legislation (the Treat and Reduce Obesity Act) could change this, but as of May 2026 it has not passed.

Compounded Tirzepatide in New Jersey

Compounded tirzepatide is available in New Jersey through licensed 503A compounding pharmacies at approximately $249 per month [7]. This represents a 76% reduction from the branded list price.

Legality and Regulatory Status

The FDA allows 503A pharmacies to compound tirzepatide when there is a valid patient-specific prescription and the drug meets shortage criteria or other compounding exemptions under the Federal Food, Drug, and Cosmetic Act [7]. New Jersey's Board of Pharmacy licenses and inspects 503A facilities operating within the state. Patients should verify that their compounding pharmacy holds a current NJ Board of Pharmacy license.

Quality Considerations

Compounded medications are not FDA-approved products. They do not undergo the same manufacturing validation, stability testing, or bioequivalence evaluation as branded Zepbound [7][8]. The Endocrine Society and the Obesity Medicine Association have issued guidance urging patients to use FDA-approved formulations when accessible and to select only pharmacies accredited by the Pharmacy Compounding Accreditation Board (PCAB) if using compounded products [8].

Dose Accuracy and Storage

Branded Zepbound uses single-dose pens with factory-calibrated dosing. Compounded tirzepatide typically comes in multi-dose vials requiring the patient to draw up each injection. Dosing errors are more common with vial-and-syringe preparation, particularly during the titration phase when doses change every 4 weeks [1][9].

The Eli Lilly Savings Card Program

Eli Lilly offers a savings card that reduces Zepbound cost to as low as $25 per monthly fill for patients with commercial insurance [10]. The program is available to New Jersey residents who meet eligibility criteria.

Eligibility Requirements

The savings card is available to patients with commercial (private) insurance. It is not available to patients enrolled in Medicare, Medicaid, TRICARE, or other federal or state government programs [10]. Patients must have a valid prescription and fill at a participating pharmacy.

How the Card Works in Practice

The savings card covers the difference between the patient's copay or coinsurance and $25, up to a maximum monthly benefit. If a patient's insurance copay is $300, the card covers $275. If the copay exceeds the card's maximum monthly cap, the patient pays the remainder. The card resets annually and Eli Lilly can modify or discontinue the program [10].

LillyDirect

Eli Lilly's LillyDirect program ships Zepbound directly to patients in New Jersey, bypassing traditional pharmacy channels. For eligible commercially insured patients, LillyDirect pricing combined with the savings card may yield the lowest out-of-pocket cost [10]. The program also offers a cash-pay option at a price below the standard retail WAC for patients without insurance coverage.

Clinical Efficacy: What the Evidence Shows

Understanding Zepbound's cost requires context on what that investment delivers. The SURMOUNT clinical trial program provides the strongest efficacy data for tirzepatide in weight management [11].

SURMOUNT-1 Results

In SURMOUNT-1 (N=2,539), participants receiving tirzepatide 15 mg lost 22.5% of body weight at 72 weeks compared to 2.4% for placebo [11]. The 10 mg dose produced 21.4% weight loss, and the 5 mg dose produced 16.0%. These results exceeded those of semaglutide 2.4 mg in the STEP-1 trial, where participants lost 14.9% at 68 weeks [12].

SURMOUNT-2 in Patients With Type 2 Diabetes

SURMOUNT-2 (N=938) studied tirzepatide in adults with obesity and type 2 diabetes [13]. Mean weight loss at 72 weeks was 14.7% with the 15 mg dose. HbA1c dropped by 2.1 percentage points. These dual effects on weight and glycemic control make Zepbound particularly cost-relevant for patients managing both conditions, since it may reduce the need for additional diabetes medications [13][14].

Cardiovascular Outcomes

The SELECT trial established cardiovascular risk reduction with semaglutide in patients with obesity [15]. Tirzepatide's own cardiovascular outcomes trial (SURPASS-CVOT) is ongoing, but secondary analyses from SURMOUNT trials show significant improvements in blood pressure, triglycerides, and waist circumference with tirzepatide [11][13]. The American Heart Association recognizes these cardiometabolic benefits as clinically meaningful for patients with obesity [5].

Telehealth Access in New Jersey

New Jersey permits telehealth prescribing of Zepbound. Patients can receive a prescription through a video or audio visit with a licensed prescriber without an in-person exam [4].

How NJ Telehealth Prescribing Works

New Jersey's telehealth parity law requires insurers to cover telehealth visits at the same rate as in-person visits [4]. A prescriber licensed in New Jersey can evaluate a patient via video, review labs, calculate BMI, and issue a Zepbound prescription that the patient fills at any in-state or mail-order pharmacy. Several national telehealth platforms operate in New Jersey and offer weight management programs that include tirzepatide prescribing.

Required Labs Before Starting

Most prescribers order baseline labs before initiating Zepbound: a comprehensive metabolic panel (to assess kidney and liver function), HbA1c, lipid panel, and thyroid function tests [1][9]. These can be completed at any Quest Diagnostics or Labcorp location in New Jersey, or through mobile phlebotomy services. Tirzepatide carries a boxed warning regarding medullary thyroid carcinoma risk observed in rodent studies, making baseline thyroid evaluation standard practice [1].

Cost Reduction Strategies for NJ Patients

Several approaches can lower what New Jersey residents actually pay for Zepbound beyond the list price.

Step 1: Check Insurance Formulary

Call the number on your insurance card and ask specifically about Zepbound (tirzepatide) coverage, tier placement, and prior authorization requirements. Request the specific criteria your prescriber must document [4].

Step 2: Apply the Savings Card

If commercially insured, enroll in the Eli Lilly savings card program before filling your first prescription [10]. The card is applied at the pharmacy counter and can be combined with insurance benefits.

Step 3: Explore Patient Assistance

Eli Lilly's Lilly Cares Foundation provides free Zepbound to qualifying uninsured patients with household income at or below 400% of the federal poverty level [10]. Applications require income verification and a prescriber signature.

Step 4: Consider Compounded Tirzepatide

For patients without insurance coverage and above income thresholds for patient assistance, compounded tirzepatide from a licensed NJ 503A pharmacy at approximately $249 per month represents the lowest-cost option [7]. Discuss this with your prescriber, who can evaluate whether a compounded product is appropriate for your situation.

Step 5: Appeal Denials

If insurance denies coverage, New Jersey patients have the right to file an internal appeal and, if denied again, an external review through the NJ Department of Banking and Insurance [4]. Include SURMOUNT trial data showing the magnitude of weight loss and cardiometabolic improvement to support medical necessity [11][13].

Dosing Schedule and What It Means for Monthly Cost

Zepbound uses a fixed titration schedule. The starting dose is 2.5 mg weekly for 4 weeks, increasing to 5 mg weekly [1]. From there, the prescriber may increase by 2.5 mg increments every 4 weeks up to a maximum of 15 mg weekly. Each box contains 4 single-dose pens (one month's supply), and the price is the same regardless of dose strength [1][10].

This flat pricing means that the per-milligram cost decreases as the dose increases. A patient on 2.5 mg pays the same $1,059 as a patient on 15 mg, which creates an unusual dynamic: the initiation phase is the least cost-effective period per unit of drug, but it is medically necessary to reduce gastrointestinal side effects [9][14].

Common Side Effects and Cost Implications

The most common adverse effects (nausea, vomiting, diarrhea, constipation) occurred in 25% to 44% of participants in SURMOUNT-1, mainly during dose escalation [11]. Some patients require anti-nausea medications such as ondansetron during titration, adding a minor cost ($10 to $30 for generic ondansetron) [9]. Slower titration reduces GI side effects but extends the time at lower, less effective doses.

Patients should budget for the full titration period (typically 20 weeks to reach 15 mg) and discuss with their prescriber whether a maintenance dose lower than 15 mg might be sufficient based on their individual response [1][14].